Ozempic for Psoriasis & Eczema: Emerging Anti-Inflammatory Evidence Review

This dermatology evidence brief is part of Weight Loss Rankings’ living editorial database — 300+ research articles and 190+ clinically-reviewed GLP-1 telehealth providers, sourced only from FDA prescribing information on DailyMed and peer-reviewed PubMed literature.

A small but persistent question keeps coming up in dermatology clinics and patient forums: can semaglutide — Ozempic for type 2 diabetes, Wegovy for chronic weight management — help with psoriasis, eczema, or other inflammatory skin conditions? The honest read of the published evidence in 2026 is that there is a real but small signal in psoriasis, the signal is almost entirely seen in patients who also have obesity or T2D (i.e., when the metabolic context is doing most of the work), the one placebo-controlled randomized trial in normoglycemic psoriasis patients was negative, and no large RCT has been conducted for any GLP-1 receptor agonist with psoriasis as the primary endpoint. Eczema/atopic dermatitis has even thinner data. Ozempic and Wegovy are not FDA-approved for psoriasis, eczema, or any dermatologic condition, and neither product’s FDA-approved label^[1][2] lists psoriasis or eczema in Section 6 Adverse Reactions.

Is Ozempic FDA-approved for psoriasis or eczema? (No)

Neither Ozempic nor Wegovy has an FDA-approved dermatologic indication. The Ozempic prescribing information^[1] lists two indications: glycemic control in adults with type 2 diabetes, and cardiovascular risk reduction in adults with T2D plus established CV disease. The Wegovy prescribing information^[2] covers chronic weight management and (since 2024) cardiovascular risk reduction in adults with established CV disease and overweight or obesity. Neither label includes psoriasis, atopic dermatitis, hidradenitis suppurativa, psoriatic arthritis, or any other dermatologic or rheumatologic indication.

Both labels’ Section 6 Adverse Reactions are also worth reading on this point. The Ozempic Section 6 does not list psoriasis or atopic dermatitis as a labeled adverse event from either clinical trials or postmarketing experience^[1]; the Wegovy Section 6 likewise does not list either condition^[2]. That is not an efficacy claim — absence from the adverse-event section means the drug has not been flagged as causing psoriasis or eczema, but says nothing about whether it might improve them. Improvement in a non-labeled condition is exactly the territory that small case series and underpowered trials can describe, and that the FDA neither evaluates nor approves through the standard NDA pathway.

Using Ozempic for psoriasis or eczema therefore falls under off-label prescribing — legal under the Practice of Medicine clause of the Federal Food, Drug, and Cosmetic Act, but not what the regulatory record supports as a primary indication. For the legal and insurance framework around off-label semaglutide use generally, see Ozempic without diabetes — the off-label landscape.

Why the question keeps coming up (biological plausibility)

The interest in GLP-1 receptor agonists for inflammatory skin conditions is not pure speculation. Three lines of biological reasoning converge to make the question legitimate, even if the clinical-trial evidence remains thin^[9][10].

1. Obesity drives a pro-inflammatory state that worsens psoriasis

Adipose tissue in obesity is not metabolically silent. Expanded adipocytes and infiltrating macrophages release TNF-α, IL-6, IL-17, and other adipokines that contribute to the systemic inflammatory milieu of obesity — the same TNF/IL-17 axis that drives psoriasis pathophysiology and that biologic-drug therapies target directly (TNF inhibitors, IL-17 inhibitors, IL-23 inhibitors). Obesity is an independent risk factor for incident psoriasis and for greater psoriasis severity in established disease; reducing adiposity reduces this systemic inflammatory load^[9][10]. Any intervention that produces substantial weight loss, therefore, has a plausible indirect path to psoriasis improvement even without acting on the skin itself.

2. GLP-1 receptors on immune cells (not principally on keratinocytes)

GLP-1 receptors are expressed on several immune-cell subsets including some T-cell populations and macrophages, and the GLP-1 RA literature describes anti-inflammatory effects in vitro and in non-dermatologic preclinical models. The Buysschaert 2014 prospective case series^[5] reported that improvement in psoriasis on liraglutide was accompanied by a reduction in dermal γδ T-cell density — an immunopathologic readout consistent with a direct immunomodulatory mechanism beyond the weight-loss effect alone. The mechanistic literature is suggestive rather than definitive: high-quality demonstration of keratinocyte-specific GLP-1R expression and a receptor-mediated dermatologic effect remains a research question, not a settled finding^[9].

3. Cardiometabolic comorbidity makes treating the patient's metabolism part of treating the psoriasis

Psoriasis is increasingly understood as a systemic inflammatory disease with cardiovascular and metabolic comorbidity (psoriatic arthritis, metabolic syndrome, non-alcoholic fatty liver disease, CV events). The National Psoriasis Foundation 2026 primer^[8] frames the rising interest in GLP-1 RAs in psoriasis explicitly within this comorbidity context — even in the absence of a dermatologic primary indication, the cardiometabolic benefits of semaglutide and tirzepatide (HbA1c improvement, weight loss, MACE reduction in the SELECT trial population for semaglutide 2.4 mg) align with the comorbid metabolic profile many psoriasis patients carry.

The early liraglutide pilot data (Buysschaert + Faurschou)

The published GLP-1 + psoriasis literature begins with case reports and small open-label series. Three early observations set the field:

• Buysschaert 2012^[4]: single case report of a T2D patient with concurrent psoriasis whose PASI score improved after starting exenatide. The original observation that opened the line of inquiry.
• Buysschaert 2014^[5]: prospective open-label case series in T2D + psoriasis patients treated with liraglutide. Reported PASI improvement alongside reduced dermal γδ T-cell density on skin biopsies — the immunopathologic readout that suggested a possible direct immunomodulatory mechanism beyond weight loss alone.
• Faurschou 2014^[6]: small open-label observational series (n=4-6) of liraglutide in T2D + psoriasis. Reported PASI improvement alongside weight loss and glycemic improvement. No placebo arm; metabolic confounding not separable from any direct effect.

These three studies, taken at face value, produced a coherent enough signal to motivate a placebo-controlled trial. That trial — the only one of its kind in the published literature — was Faurschou and colleagues’ 2015 randomized placebo-controlled trial of liraglutide specifically in glucose-tolerant psoriasis patients, designed to isolate the dermatologic effect from the metabolic confounding^[7].

The 2026 expert-society reviews^{[8][9][10][11]} all cite this same evidence trajectory: positive case-series signal in metabolically-impaired psoriasis patients, negative placebo-controlled RCT in metabolically-normal psoriasis patients, and a default-current interpretation that the clinically meaningful effect (when it appears) is principally mediated by weight loss and glycemic improvement.

Weight loss itself improves psoriasis (Naldi 2014)

The weight-loss-as-mediator framing is supported by a separate body of evidence in which the intervention is weight loss directly, with no GLP-1 involvement. The Naldi and colleagues 2014 randomized controlled trial^[8] — published in the British Journal of Dermatology, not (as commonly misattributed) a Cochrane review — randomized overweight psoriasis patients to a 20-week dietary intervention plus physical exercise vs an informational booklet. The intervention arm achieved greater weight loss and a modestly greater improvement in psoriasis severity (PASI) at the 20-week endpoint than the control arm^[8].

The Naldi RCT effect size is small in absolute terms but directionally consistent with the broader pattern: in overweight or obese psoriasis patients, any intervention that produces meaningful weight loss tends to produce some psoriasis improvement, in proportion to the magnitude of the weight reduction.

The reasonable inference — and it is an inference, not a tested claim — is that an intervention that produces ~15% mean body-weight reduction (semaglutide 2.4 mg in STEP-1^[3]) should produce more psoriasis improvement than an intervention that produces ~2.5% body-weight reduction (Naldi 2014 lifestyle arm^[8]), via the same weight-loss-mediated pathway. This is the testable hypothesis the 2026 expert reviews^[9][10] identify as the most important next research question: a properly-powered RCT of semaglutide or tirzepatide at the full anti-obesity dose in overweight or obese psoriasis patients with PASI as a primary or co-primary endpoint. That trial has not yet been published.

Where is the semaglutide-specific data? (the gap)

Nearly all of the published GLP-1 RA + psoriasis evidence is on liraglutide, not on semaglutide — Ozempic, Wegovy, or Rybelsus. There are reasons for this. Liraglutide was the first widely-used GLP-1 RA for both T2D (Victoza, 2010) and obesity (Saxenda, 2014); the early endocrinology clinics that first noticed the dermatologic co-improvement were prescribing liraglutide. Semaglutide only arrived clinically in 2017 (Ozempic) and 2021 (Wegovy at the higher weight-management dose), and the dermatology literature has not yet caught up.

Concretely, as of 2026, the published-evidence picture for semaglutide specifically in psoriasis consists of:

• No pivotal RCT of semaglutide (Ozempic, Wegovy, or Rybelsus) with psoriasis as the primary endpoint.
• No FDA-approved indication for semaglutide in psoriasis, atopic dermatitis, psoriatic arthritis, or hidradenitis suppurativa^[1][2].
• Case reports and small retrospective observations that mention psoriasis improvement alongside weight loss on semaglutide, synthesized in the 2026 review literature^{[8][9][10][11]}.
• Mechanistic and epidemiologic extension studies that look at downstream cardiovascular events in psoriasis or eczema patients on GLP-1 RAs (e.g., Braun and colleagues 2025^[12] in atopic dermatitis + T2D) — without measuring skin severity directly.

For a patient or clinician trying to make a decision today, the honest summary is that semaglutide-specific psoriasis efficacy is extrapolated from the liraglutide case-series literature, the negative liraglutide RCT, the weight-loss-mediator RCT (Naldi 2014), and the general weight-loss magnitude of semaglutide at the Wegovy dose (STEP-1). It is not yet directly demonstrated.

For background on semaglutide and the broader GLP-1 class generally, see Full GLP-1 medication list reference and Wegovy vs Ozempic: same molecule, different labels.

What about eczema / atopic dermatitis?

The eczema (atopic dermatitis) evidence base for GLP-1 RAs is even thinner than the psoriasis one, and the existing studies measure different endpoints than skin severity. The two most relevant published works in 2025-2026:

• Braun and colleagues 2025^[12] (J Am Acad Dermatol): population-level observational study showing that GLP-1 RA use in adults with atopic dermatitis plus T2D is associated with reduced major adverse cardiovascular events (MACE). Important caveat: the endpoint is cardiovascular events, not eczema severity. The atopic dermatitis status is being used as the cohort selector (because AD patients have elevated CV risk), not as a treated outcome. The study does not demonstrate that GLP-1 RAs improve eczema.
• Narla & Narla 2026 JAAD CME review^[11]: the dermatology continuing-medical-education companion overview covering the broader GLP-1 RA dermatologic literature including atopic dermatitis — consistent with the other 2026 reviews in framing AD as a biologically-plausible but clinical-evidence-thin extension.

Mechanistically, atopic dermatitis is a Th2-driven condition (IL-4, IL-13, IL-31 axis), pharmacologically distinct from the Th17/IL-17/IL-23-driven pathophysiology of psoriasis. The case for GLP-1 RA benefit in eczema is therefore less biologically obvious than the case in psoriasis. Obesity is still associated with eczema severity, so the weight-loss-mediator path remains coherent, but the case-series and small-trial signal that exists for psoriasis simply has not been reproduced for atopic dermatitis.

Practical bottom line for eczema: there is no clinical-evidence basis to use Ozempic, Wegovy, or any GLP-1 RA off-label for atopic dermatitis treatment in 2026. If a patient with eczema and obesity is a candidate for weight-management therapy on its own merits, the eczema is a comorbidity that may or may not improve secondarily — not a separate treatment indication.

Practical guidance for psoriasis plus obesity patients

For a patient with both psoriasis and obesity, the practical framing in 2026 is straightforward:

1. Treat the psoriasis with FDA-approved psoriasis therapy. Topicals, phototherapy, conventional systemic immunosuppressants (methotrexate, cyclosporine, apremilast), and biologic therapies (TNF, IL-17, IL-23, IL-12/23 inhibitors) remain the standard of care, prescribed by a dermatologist on the basis of severity and comorbidity. GLP-1 RAs do not replace these therapies.
2. Treat the obesity on its own clinical merits. If the patient meets BMI criteria (≥30 or ≥27 with weight-related comorbidity) and is a candidate for anti-obesity pharmacotherapy, Wegovy is FDA-approved for that indication; tirzepatide (Zepbound) is similarly approved at higher weight-loss magnitudes. Psoriasis itself can be documented as a weight-related comorbidity for prior authorization purposes.
3. Expect secondary skin benefit proportional to weight loss. Based on the available evidence — the weight-loss-mediator RCT (Naldi 2014^[8]), the case-series literature (Buysschaert 2014^[5], Faurschou 2014^[6]), and the 2026 expert-society syntheses^[9][10] — some improvement in psoriasis severity is plausible alongside meaningful weight loss in patients with obesity-associated psoriasis. The magnitude is not predictable in advance and should not be the primary motivation for initiating GLP-1 therapy.
4. Coordinate with your dermatologist. If you start a GLP-1 RA primarily for obesity, tell your dermatologist; some psoriasis biologic-therapy dosing or monitoring decisions may shift as weight changes. Conversely, if your psoriasis improves on a GLP-1, do not stop your dermatology therapy without your dermatologist’s input — the improvement is unlikely to be sustained if the underlying psoriasis therapy is withdrawn.
5. Do not use Ozempic off-label as a skin-only therapy. The evidence does not support that strategy. The one placebo-controlled RCT in glucose-tolerant psoriasis patients was negative^[7]. Off-label use of Ozempic specifically for psoriasis in a normal-weight, normoglycemic patient is not insurance-covered, not FDA-approved, and not supported by the published efficacy literature.

For the first-month practical playbook on starting semaglutide, see Starting Wegovy — what to expect in the first month and the broader alternatives landscape in Wegovy alternatives in 2026. For a related GLP-1-meets-organ-system clarifier article, see Wegovy for MASH / MAFLD fatty liver: evidence review — the same comorbidity-vs-direct-indication framing applies.

Frequently asked questions

Related research

• Full GLP-1 medication list reference — every FDA-approved GLP-1 with brand, manufacturer, indication, dose ladder, and DailyMed SetID links.
• Wegovy vs Ozempic: same molecule, different labels — head-to-head evidence review of the two semaglutide products that are relevant to any off-label dermatology discussion.
• Wegovy for MASH / MAFLD fatty liver: evidence review — sister-indication article applying the same comorbidity-vs-direct-indication framing to NASH.
• Ozempic without diabetes — off-label use for weight loss — the legal and insurance framework around off-label semaglutide use.
• Wegovy alternatives in 2026 — the broader anti-obesity-therapy landscape including tirzepatide-class options.
• Starting Wegovy — what to expect in the first month — the practical first-month playbook for any patient initiating semaglutide therapy.

Important disclaimer. This article is educational information only — not medical advice and not a substitute for consultation with a licensed prescriber or dermatologist. Ozempic, Wegovy, and other GLP-1 receptor agonists are prescription medications with boxed warnings and contraindications. Psoriasis, eczema, and other inflammatory skin conditions are complex disorders requiring dermatology-specialist care. Every clinical decision involving GLP-1 therapy or dermatology therapy must be made with licensed prescribers who have reviewed the full FDA prescribing information and the individual patient’s history. Every clinical claim in this article is anchored to a primary source (DailyMed or PubMed). Weight Loss Rankings does not prescribe, dispense, or endorse any specific medication.